	US 11,940,450 B2
	Biomarker panel for non-invasive diagnosis of congenital renal dysfunction
Linda H. Shapiro, Middlebury, CT (US); Fernando A. Ferrer, Sunny Isles Beach, FL (US); Charan Devarakonda, Vernon, CT (US); and James J. Grady, Farmington, CT (US)
Assigned to UNIVERSITY OF CONNECTICUT, Farmington, CT (US)
Filed by UNIVERSITY OF CONNECTICUT, Farmington, CT (US)
Filed on Mar. 15, 2022, as Appl. No. 17/695,381.
Claims priority of provisional application 63/161,601, filed on Mar. 16, 2021.
Prior Publication US 2022/0299530 A1, Sep. 22, 2022
Int. Cl. G01N 33/543 (2006.01); G01N 33/68 (2006.01)

CPC G01N 33/6893 (2013.01) [G01N 33/54306 (2013.01); G01N 2470/06 (2021.08); G01N 2800/285 (2013.01); G01N 2800/385 (2013.01); G01N 2800/50 (2013.01)]

11 Claims

1. A method for treating ureteropelvic junction obstruction (UPJO) in a subject, wherein the subject is a human child, comprising:

(a) detecting in a urine sample from the subject one or more proteins selected from the group consisting of Immunoglobulin superfamily containing leucine-rich repeat protein (ISLR); Nicotinate-nucleotide pyrophosphorylase [carboxylating] (QPRT); Prostaglandin reductase 1 (PTGR1); Vascular cell adhesion protein 1 (VCAM1); and Ficolin-2 (FCN2);

(b) comparing an amount of the one or more proteins in the urine sample to a standard;

wherein the subject has an increase in the amount of at least one of the one or more proteins in the urine sample above the standard, diagnosing the subject as having UPJO; and